NEW YORK, Oct. 22 – NetGenics has licensed its DiscoveryCenter integration software product to Avalon Pharmaceuticals to help it integrate its genomic, cytogenetic, and chemistry data, Avalon said on Monday.

“We are building the next generation genomics drug discovery platform,'' Ken Carter PhD, Avalon's president and CEO, said in a statement. “DiscoveryCenter will play a key role in our success, as it provides us with the ability to integrate and analyze huge amounts of data, and NetGenics will provide a fundamental building block to our cutting edge bioinformatics platform.''

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.